WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Monday March 14, 2011 at 4:30 p.m. EDT, to discuss results of a Phase 3 clinical trial of RG1068 in MRI imaging of the pancreas. This call is being webcast by Thomson/CCBN and can be accessed via Repligen’s website at www.repligen.com. You may also listen to the live broadcast by calling (800) 299-9086 for domestic calls and (617) 786-2903 for international calls. Participants must provide the following passcode: 58319328. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call on Repligen’s website www.repligen.com.
